

Neuralstem, Inc.  
Form 8-K  
June 26, 2015

---

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

---

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

**Date of report (Date of earliest event reported): June 26, 2015**

---

**Neuralstem, Inc.**

**(Exact name of registrant as specified in Charter)**

<b>Delaware</b> <b>(State or other jurisdiction of incorporation or organization)</b>	<b>000-1357459</b> <b>(Commission File No.)</b>	<b>52-2007292</b> <b>(IRS Employee Identification No.)</b>
--	--	---

**20271 Goldenrod Lane, 2<sup>nd</sup> Floor, Germantown, Maryland 20876**

**(Address of Principal Executive Offices)**

**(301) 366-4960**

**(Issuer Telephone number)**

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events.**

On June 26, 2015, Neuralstem, Inc. (the “Company”) announced that a poster entitled “Human Neural Stem Cells Expressing IGF-1: A Novel Cellular Therapy for Alzheimer’s Disease” was presented at the International Society for Stem Cell Research Annual Meeting in Stockholm, Sweden. A copy of the press release and poster are attached to this report as Exhibits 99.01 and 99.02, respectively.

**Item 9.01 Financial Statement and Exhibits.**

**Exhibit No. Description**

99.01	Press Release Dated June 26, 2015.
99.02	Poster presented at Meeting.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 26, 2015 Neuralstem, Inc.

/s/ Richard Garr  
By: Richard Garr  
Chief Executive Officer

**INDEX OF EXHIBITS**

**Exhibit No. Description**

99.01 Press Release Dated June 26, 2015.

99.02 Poster presented at Meeting.